Aims/hypothesis: Peroxisome proliferator-activated receptor (PPAR) γ agonists are used increasingly in the treatment of type 2 diabetes. In the context of renal disease, PPARγ agonists reduce microalbuminuria in diabetic nephropathy; however, the mechanisms underlying this effect are unknown. Glomerular podocytes are newly characterised insulin-sensitive cells and there is good evidence that they are targeted in diabetic nephropathy. In this study we investigated the functional and molecular effects of the PPARγ agonist rosiglitazone on human podocytes. Methods: Conditionally immortalised human podocytes were cultured with rosiglitazone and functional effects were measured with glucose-uptake assays. The effect of rosiglitazone on glucose u...
We aimed to determine whether epidermal growth factor receptor (EGFR) inhibition, in addition to a p...
Aquaporin 2 (AQP2) is the vasopressin-regulated water channel palying a crucial role in urine concen...
MastersNephropathy is one of the major clinical manifestations of microvascular disease in diabetic ...
AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor (PPAR) gamma agonists are used increasin...
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors and play a cen...
Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence...
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.Ba...
Peroxisome proliferator-activated receptor (PPAR), a ligand-dependent transcription factor, negative...
Aims: To accommodate surplus energy, adipose tissue expands by increasing both adipose cell size (hy...
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with d...
Rosiglitazone is a PPARγ agonist commonly used to treat diabetes. In addition to improving insulin s...
Background: Rosiglitazone (Ros) has been shown to attenuate CXCL8 and ICAM-1 overexpression in renal...
Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for ...
Fibrate peroxisome proliferator-activated receptor (PPAR)-α ligands are mainly used as hypolipidemic...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
We aimed to determine whether epidermal growth factor receptor (EGFR) inhibition, in addition to a p...
Aquaporin 2 (AQP2) is the vasopressin-regulated water channel palying a crucial role in urine concen...
MastersNephropathy is one of the major clinical manifestations of microvascular disease in diabetic ...
AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor (PPAR) gamma agonists are used increasin...
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors and play a cen...
Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence...
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.Ba...
Peroxisome proliferator-activated receptor (PPAR), a ligand-dependent transcription factor, negative...
Aims: To accommodate surplus energy, adipose tissue expands by increasing both adipose cell size (hy...
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with d...
Rosiglitazone is a PPARγ agonist commonly used to treat diabetes. In addition to improving insulin s...
Background: Rosiglitazone (Ros) has been shown to attenuate CXCL8 and ICAM-1 overexpression in renal...
Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for ...
Fibrate peroxisome proliferator-activated receptor (PPAR)-α ligands are mainly used as hypolipidemic...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
We aimed to determine whether epidermal growth factor receptor (EGFR) inhibition, in addition to a p...
Aquaporin 2 (AQP2) is the vasopressin-regulated water channel palying a crucial role in urine concen...
MastersNephropathy is one of the major clinical manifestations of microvascular disease in diabetic ...